Webcast

Dr. Hynicka is an associate professor of pharmacotherapy at the University of Maryland School of Pharmacy. She served as a clinical pharmacy specialist on a general internal medicine team at the University of Maryland Medical Center for six years before transitioning into her current role, where she manages the treatment of HCV patients in an ambulatory clinic. Her teaching, research, and patient care activities focus on the care of patients with chronic liver diseases including; viral hepatitis B and C and nonalcoholic fatty liver disease. Recent areas of research include streamlining the prior authorization process for HCV medications at a large academic health system, evaluating HCV treatment interruptions, and evaluating the uptake of the 8-week Harvoni medication regimen.

Kimberly A. Forde, MD, PhD, MHS, is an Associate Professor of Medicine, in the Section of Hepatology, Department of Medicine, at the Temple University Hospital, Lewis Katz School of Medicine. Dr. Forde earned her Bachelor of Arts degree in Biology from Barnard College and her medical degree from Columbia University, College of Physicians and Surgeons. She completed her Internal Medicine Residency at New York Presbyterian Hospital (Columbia University), with subspecialty training in Gastroenterology and Hepatology, at the University of Pennsylvania where she also served as Chief Fellow. Dr. Forde’s research interests include the epidemiology of viral hepatitis and outcome assessment in patients with acute and chronic liver failure. Dr. Forde is a prolific writer, having authored more than 70 peer reviewed articles in high impact journals such as the New England Journal of Medicine, Gastroenterology and Hepatology. In addition to her research and teaching, she has served on several national committees, including the Clinical Research Committee of the American Association for the Study of Liver Diseases and the nominating Committee for the American Gastroenterological Society.

r. Sharon Cohen, MD, FRCP, is a behavioural neurologist and the medical director of the Toronto Memory Program, a community-based medical facility which she established in 1996 for the purpose of enhancing diagnosis and treatment for individuals with Alzheimer’s disease and related disorders. Her memory clinic and dementia research site are among the most active in Canada. Dr. Cohen has over 28 years of experience in clinical research and has been a site primary investigator for over 180 pharmacological trials in dementia, including phase 1 trials. She represents Canada on international advisory boards and steering committees and is a consultant to a wide range of stakeholders including government organizations and patient advocacy groups. She is a frequent lecturer and contributes to media events including those on medical ethics. Additionally, she is known for her advocacy of individuals with neurodegenerative diseases.

Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real-world setting.

Rachel received her Master of Science in Genetic Counseling from the University of South Carolina School of Medicine in May 2017 and was certified by the American Board of Genetic Counseling (ABGC) in August 2017. Rachel completed a genetic counseling fellowship in lysosomal storage diseases at Ann & Robert H. Lurie Children’s Hospital, focusing on diagnosis, management, treatment, and newborn screening for this group of complex diseases.

She currently provides genetic counseling services in the pediatric setting, continuing to specialize in lysosomal storage diseases as well as general genetics. She serves as the clinic coordinator for the Leukodystrophy Clinic at Lurie Children’s Hospital and is the primary coordinator for this center’s Krabbe Disease and X-Linked Adrenoleukodystrophy Newborn Screening Programs.

Dr. Laura Adang is an Assistant Professor of Child Neurology at the Children’s Hospital of Philadelphia specializing in the care of children with leukodystrophies. Dr. Adang is a magna cum laude graduate of the University of Georgia’s Foundation Fellowship scholarship program and a graduate of the Medical Scientist Training Program at the University of Virginia, where she received both her MD and PhD. Her graduate work in the laboratory of Dean H. Kedes, MD, PhD characterized the immune evasion mechanisms of herpesvirus infections. Her work has been published in NEJM, Cell, and Journal of Clinical Investigations among others.

After graduating from the University of Virginia, she completed her pediatrics and child neurology residencies at the Children’s Hospital of Philadelphia and the University of Pennsylvania. She completed additional fellowship training in multiple sclerosis and leukodystrophies and a Masters of Translational Research at the Institute for Translational Medicine and Therapeutics (ITMAT) of the Perelman School of Medicine at the University of Pennsylvania. Her primary research focus is clinical trial readiness for leukodystrophies, including metachromatic leukodystrophy.

Florian S. Eichler, MD, is an Associate Professor of Neurology at Massachusetts General Hospital (MGH) and Harvard Medical School. He is the Director of the Leukodystrophy Service, the Center for Rare Neurological Diseases at MGH, and the Mass General Brigham Neurogenetics and Gene Therapy Fellowship. He runs a laboratory at MGH that explores the relationship of mutant genes to specific biochemical defects and their contribution to neurodegeneration. To develop novel treatments, his laboratory assesses the consequences of disease-causing genes. The laboratory identified two neurotoxic desoxysphingoid bases that accumulate in mutant transgenic mice and humans with hereditary sensory neuropathy type 1 (HSAN1). This work led to the first clinical trial of substrate supplementation therapy for patients with HSAN1 (NCT01733407).

Dr Eichler is the principal investigator of several NIH-funded studies on neurogenetic disorders as well as a gene therapy trial of adrenoleukodystrophy (NCT01896102) that reported on first successful outcomes in the New England Journal of Medicine. For this work, he received the Martin Research Prize from MGH and the Herbert Pardes Clinical Excellence Award from the Clinical Research Forum.

In response to the HIV pandemic, Dr. Wohl has focused his career on optimizing the treatment of HIV infection, including identifying the most effective therapeutic approaches and minimizing the adverse effects of therapy. Cognizant that HIV disproportionately affects the most vulnerable, he has worked to improve HIV care and prevention for often marginalized individuals such as the incarcerated, men who have sex with men, and those living in poverty.

Dr. Wohl is active within the U.S. AIDS Clinical Trials Group (ACTG) and HIV Prevention Trials Network (HPTN), and served two terms as a member of the U.S. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines and was recently invited to serve on the DHHS Panel on Opportunistic Infection Guidelines.

As part of the response to the 2013-2016 Ebola outbreak in West Africa, Dr. Wohl led UNC clinical research efforts to test interventions for Ebola Virus Disease in Liberia and now is a principal investigator of a clinical cohort that longitudinally follows Ebola survivors, as well as a study to determine the natural history of Lassa fever.

In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC.

Margot Savoy, MD, MPH, FAAFP, FABC, CPE, CMQ, FAAPL is Associate Professor for the Department of Family & Community Medicine at the Lewis Katz School of Medicine at Temple University and Temple University Hospital, and Chief Quality Officer for the Temple Faculty Practice Plan. She is an attending physician at Temple University Hospital (Philadelphia, PA) and Christiana Care Health System (Wilmington, DE). Dr. Savoy graduated from the University of Maryland School of Medicine in 2002, completed Family Medicine Residency Program at the Crozer-Keystone Family Medicine Residency Program (Springfield, PA) in 2005, and graduated from the University of North Carolina Chapel Hill Gillings School of Global Public Health in 2008 with a Master’s degree in Public Health in Public Health Leadership with a focus on Public Health Practice. She is certified by the American Board of Family Medicine, the Certifying Commission in Medical Management, and is a Fellow of the Advisory Board Company.

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, SC.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine, and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia, and circadian rhythm abnormality.